4Wensing A M, van de Vijver D A, Angarano G, etal. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe : Implications for clinical management[J]. J Infec Dis, 2005,192 (6):958 - 966.
5Gallant J E. Antiretroviral drug resistance and resistance testing[J]. Top HIV Med, 2005,13(5) :132- 142.
6Johnson V A, Brun Vezinet F, clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006[J]. Special Contribution-Resistance Mutations, 2006,14(3) : 125 - 130.
7Cane P, Chrystie I, Dunn D, etal. Time trends in primary resistance to HIV drugs in the United kingdom; multicentre observational study[J]. BMJ, 2006,332 (7534) : 179 - 180.
8Ross L, lim M I., Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities[J]. HIV Clin trials, 2007,8: 1 -8.
9Seyler C, Adje-Toure C, Messou E, et al. Impact of genotypic drug resistance mutations on clinical and immunological out comes in HIV infected adults on HAART in West Africa[J]. AIDS, 2007,21 (9) : 1157 - 1164.
10Tobin N, Frenkel L. Human immunodeficiency virus drug susceptibility and resistance testing[J]. Pediatr Infect Dis, 2002,21:668 - 683.
4Moroni M. Genotypic resistance tests for the management of patients with vitro-immunological disordant response to highly active antireoviral therapy. Scand J Infect Dis Suppl, 2003, 106: 85-87.
5Puro V. Genotypic resistance tests for the management of post exposure prophylaxis. Scand J Infect Dis Suppl, 2003, 106: 93-98.
6杰伊A利维.艾滋病病毒与艾滋病的发病机制[M].北京:科学出版社,2000.282-303.
7Maga G, Hübscher U, Pregnolato M, et al. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and D-and-L-(β)-dideoxynucleoside T tiphosphae analogs. Antimicrobial Agents and Chemotherapy, 2001, 45(4 ): 1192-1200.
8de Ronde A, van Dooren M, van der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol, 2001, 75(2): 591-602.
9Eric J, Miguel E, Quiňones-Mateu, et al. 3′-azdio-3′-deoxythymidine(AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human iImmunodeficiency virus type 1 variants. J Virol, 1998, 72 (6): 4858-4865.
10Callant JE,Cerondclis PZ,Wainberg MA,ct al.Nuclcosidc and nuclcotide analoguc reversc transcriptasc inhibitors:a clinical revicw of antiretroviral resistance[J].Antivir Ther,2003,8:489-506.
9Sehultz, ST, Willis JH. Individual variation in inbreeding depression: the roles of inbreeding history and mutation [J]. Genetics, 1995, 11 (141) :1209.
